Leukemia and Lymphoma
Web Exclusives | May 15, 2018
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
With 5-year survival rates for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) at 86% and 71%, respectively, the number of lymphoma survivors is on the rise, but achieving long-term quality of life after treatment is completed remains an ongoing challenge.
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
Treatments targeting immune responses against solid tumors have led to dramatic improvements in patient outcomes, but the role for immunotherapy in the treatment of acute leukemia is still being defined.
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
After nearly 40 years of negligible drug development, 2017 saw the approval of 4 drugs by the FDA for the treatment of acute myeloid leukemia (AML).
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
On August 1, 2017, the FDA approved enasidenib (Idhifa), an isocitrate dehydrogenase-2 inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have the IDH2 genetic mutation.
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
The FDA, on August 3, 2017, approved a fixed combination daunorubicin plus cytarabine (Vyxeos) injection for the treatment of adults with 2 types of acute myeloid leukemia (AML)—newly diagnosed, therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC).
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
Tisagenlecleucel (Kymriah), a genetically modified chimeric antigen receptor (CAR) T-cell immunotherapy, was approved by the FDA on August 30, 2017, for the treatment of pediatric patients and young adults aged ≤25 years with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
On September 1, 2017, the FDA approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), as well as patients aged ≥2 years with relapsed or refractory CD33-positive AML.
Tara Albrecht, PhD, ACNP-BC, RN, Justin E. Bala-Hampton, DNP, MPH, RN, AGACNP-BC, Linda Dudjak, PhD, RN, Margaret Q. Rosenzweig, PhD, FNP-C, AOCN, FAAN
June 2017 Vol 8, No 6 | June 1, 2017
The authors explore the concept of perceived economic hardship and economic distress among a cohort of adult patients at least 6 months postdiagnosis of AML.
Joanne S. Buzaglo, PhD, Clare Karten, MS, Margaret L. Longacre, PhD, Melissa F. Miller, PhD, MPH, Eberechukwu Onukwugha, MS, PhD, Elisa S. Weiss, PhD
April 2017 Vol 8, No 4 | April 12, 2017
The authors present their findings on a study addressing interventions that foster patient-clinician communication and referral for services related to both financial need and psychosocial distress to ensure optimal adherence to CML therapy.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512